MedTrace Logo

Ketamine + Cognitive Training for Suicidality in the Medical Setting

NCT04578938 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-03-24

No results posted yet for this study

Summary

This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

Conditions

  • Suicide, Attempted

Interventions

DRUG

Intravenous ketamine

Single subanesthetic infusion of ketamine (0.5mg/kg)

BEHAVIORAL

Cognitive training

8 sessions of computer-based cognitive training

BEHAVIORAL

Sham Training

8 sessions of computer-based sham training

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Rebecca Price

    lead OTHER

Principal Investigators

  • Rebecca B Price, PhD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2026-12-02
Completion
2026-12-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04578938 on ClinicalTrials.gov